(Q33640512)

28 July 2017

title

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis (English)

1 reference

28 July 2017

main subject

Pseudomonas aeruginosa

0 references

0 references

0 references

Jerry A Nick

1

1 reference

28 July 2017

Samuel M Moskowitz

2

1 reference

28 July 2017

James F Chmiel

3

1 reference

28 July 2017

Anna V Forssén

4

1 reference

28 July 2017

Sun Ho Kim

5

1 reference

28 July 2017

Milene T Saavedra

6

1 reference

28 July 2017

Lisa Saiman

7

1 reference

28 July 2017

Jennifer L Taylor-Cousar

8

1 reference

28 July 2017

David P Nichols

9

1 reference

28 July 2017

publication date

1 March 2014

1 reference

Proceedings of the American Thoracic Society

28 July 2017

published in

1 reference

28 July 2017

volume

11

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

342-350

1 reference

Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Effects of azithromycin in Pseudomonas aeruginosa burn wound infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Interaction revisited: the difference between two estimates

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Quantification of biofilm structures by the novel computer program comstat

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Interaction 3: How to examine heterogeneity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Effect of Calcium and Magnesium Ions on the Susceptibility of Pseudomonas Species to Tetracycline, Gentamicin Polymyxin B, and Carbenicillin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4028742

Predictors of mortality in adults with cystic fibrosis

21 June 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Microbiological and immunologic considerations with aerosolized drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201310-352OC

Interactions of Macrolide Antibiotics (Erythromycin A, Roxithromycin, Erythromycylamine [Dirithromycin], and Azithromycin) with Phospholipids: Computer-Aided Conformational Analysis and Studies on Acellular and Cell Culture Models

21 January 2018

1 reference

12 December 2020

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

12 December 2020

Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome

1 reference

12 December 2020

Is the type of chronic pulmonary infection a determinant of lung function outcomes in adult patients with cystic fibrosis?

1 reference

12 December 2020

The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing

1 reference

12 December 2020

10.1513/ANNALSATS.201310-352OC

Identifiers

DOI

1 reference

28 July 2017

1 reference

28 July 2017

1 reference